43 results about "Urolithin" patented technology

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and / or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Disclosed is a method of preparing a urolithin, or an intermediate or analog thereof, having a dibenzo[b,d]pyran-6-one core. The method is especially advantageous for the large-scale preparation of urolithins or intermediates or analogs thereof. The method may optionally include the preparation of a urolithin, or an intermediate or analog thereof, as a pharmaceutically acceptable salt.

The present invention provides: a novel microorganism that has high urolithin-production capability; and a production method for urolithins that uses the novel microorganism. A microorganism that belongs to genus Eggerthella and produces urolithins.

The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and / or prophylaxis of a muscle-related pathological condition.

The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and / or prophylaxis of a muscle-related pathological condition.

The present invention addresses the problem of providing a method for eliminating the hydroxyl group at the 9-position of an urolithin in order to produce another urolithin. This problem is solved bya method for producing second urolithin, the method including a step (a) for causing a microorganism, which is capable of producing a second urolithin from a first urolithin, to produce the second urolithin from the first urolithin, in a solution containing the first urolithin.

The invention provides urolithin PDE2 inhibitor compounds and a preparation method thereof, and belongs to the field of medicinal chemistry. Two types of compounds are obtained through two-step simple reaction, and 22 brand-new PDE2 inhibitor compounds are obtained in total; the method for synthesizing the compounds is simple, convenient, energy-saving and environment-friendly; in a first step, the reaction is simple, column chromatography is not needed, the purity is high, the yield is high, and the total yield is 54% or above; and in the second step, the reaction is carried out at room temperature, no by-product is generated, the purity and yield of the target product are greatly improved, the HPLC purity of the obtained compounds is high and reaches 97% or above, and the total yield is high and reaches 30.0% or above.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of ellagic acid and metabolites thereof as natural inhibitors to preparation of an anti-pyroptosis medicine. The inventor finds that high glycolipid has a promotion effect on pyroptosis of pancreatic cells and liver cells, and expression levels of pyroptosis proteins GSDMD and GSDME in a pyroptosis signal path are increased, which indicates that pyroptosis plays a role in high-glucose and high-fat induced pancreatic and liver inflammatory reactions. GSDMD and GSDME mediated pyroptosis participates in diabetes pancreas and liver injury. It is found for the first time that the ellagic acid and intestinal tract metabolite uridine A thereof can inhibit GSDMD and GSDME mediated pyroptosis in an in-vivo experiment of a diabetic model mouse, and therefore, an anti-inflammatory protection effect on cells is achieved.

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and / or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

The invention provides application of urolithin A and derivatives thereof in tumor immunotherapy, and belongs to the technical field of biological medicine and molecular biology. According to the application, the research results show that the urolithin A and the derivatives thereof can promote the effector function of CD8 + T cells and other TCR pathway mediated activated effector T cells or artificially prepared effector T cells (including but not limited to CAR-T and TCR-T cells) so as to improve the tumor immunotherapy effect, such that the understanding of the urolithin A is effectively broadened. Regulation and control of the urolithin A on CD8 + T cell functions further reveals interaction of flora metabolites and an immune system, a theoretical basis is provided for deeply excavating more metabolites for regulating and controlling immunity, a promising immunotherapy strategy is provided for tumor patients, and therefore the urolithin A has good practical application value.

The invention discloses an application of urolithin A in prevention and treatment of allergic rhinitis and allergic asthma, and the urolithin A is used for treating allergic airway diseases by adjusting lung tissue TXNIP / NLRP3 pathway related proteins. The inventor finds that the urolithin A can significantly improve multiple inflammatory indexes of mice with allergic airway diseases, and compared with ellagic acid, the urolithin A has the effects of improving the nose scratching frequency of the mice in a disease model group, reducing the levels of IL-5, IL-4 and IL-18 in BALF, and improving the inflammatory index of the mice with allergic airway diseases. The traditional Chinese medicine composition has better effects on relieving lung eosinophilic granulocyte infiltration and goblet cell hyperplasia, reducing pathological scores of bronchial and perivascular inflammatory cell infiltration degrees, increasing the level of anti-oxidation factors GSH of lung tissues, reducing TXNIP, ASC and IL-1beta protein expression of the lung tissues and reducing the proportion of NLRP3 and TXNIP positive cells.

The invention relates to the compound urolithin A and its compositions for topical use in inflammatory skin conditions of various etiologies. Anti-inflammatory activity has been demonstrated in vivo in a model of inflammation of the ear caused by infiltration with dinitrochlorobenzene in rats. Topical application of an ointment containing 0.2 and 1.0% urolithin A resulted in a decrease in ear edema and scratching frequency, which was associated with a decrease in the number of immune cells responsible for the progression of inflammation. The results obtained indicate the possibility of using a composition containing urolithin A in local therapy of skin inflammations, in treatment of which hydrocortisone or other steroids are currently used.

The invention discloses a benzo [c] benzopyrone derivative and application thereof. A series of chemical derivatives containing a Uro B skeleton (benzo [c] benzopyrone) as shown in a formula (I) are designed and synthesized by introducing different N-terminal end groups into a urolith derivative through a 1, 3-dibromopropane bridge chain. The invention can be applied to preparation of various anti-tumor drugs and is especially suitable for bladder cancer.

A composition comprising: a)nicotinamide riboside and b)a urolithin which is a compound of formula (I) or a salt thereof: Formula (I) wherein: A, B, C and D are each independently selected from H andOH; W, X and Y are each independently selected from H and OH; and Z is selected from H and OH. The compositions are useful as medicaments, for example for treating muscle-related pathological conditions, neurodegenerative diseases, and / or mitochondrial diseases and as dietary supplements, functional foods and beverages, and specialised nutrition or medical foods.

The application belongs to the technical field of pharmaceutical preparations and discloses application of a metabolite Urolithin A of ellagic acid in preparation of anti-enterovirus drugs, particularly drugs for preventing and treating enterovirus 71 (EV71). According to the application, through influence on titer and protein expression of the EV71 caused by UroA, it is shown that the Urolithin Acan inhibit replication of the EV71 in gene and protein levels. It is proven that the Urolithin A has an obvious anti-EV71 action and can be used for preparing anti-EV71 drugs.

The invention relates to a urolithin compound which has a structure as shown in the specification. The compound shows very strong anti-glioblastoma activity in vitro, can be matched with a medicinal carrier, and is used for preparing various medicinal dosage forms for treating anti-glioblastoma, such as capsules, granules, oral liquid or tablets.

A urolithin-containing aqueous solution containing urolithin and collagen, a dried solid composition thereof, methods for producing these, and a stabilization method for urolithin.

The invention provides compounds of formula (I) or salts thereof:wherein:A, B, C, D, W, X, Y and Z are as defined in the specification, and at least one of A, B, C, D, W, X, Y and Z is OR1; each R1 being independently H or C(═O)R2, and at least one R1 group being C(═O)R2; where each R2 is selected from:CHR3NHR4, where R4 is H and R3 is a group selected from CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2Ph, CH2-3-(1H-indole), CH2CH2SCH3, CH2OH, CHOHCH3, CH2SH, CH2SeH and CH2PhpOH,wherein said R3 group can optionally be substituted by one or more groups selected from halogen, cyano, nitro, ORA or C1-C4 alkyl;or R3 and R4 together with the C and N atoms to which they are attached form a 5-membered heteroalkyl ring, wherein said heteroalkyl ring can optionally be substituted by one or more groups selected from halogen, cyano, nitro, ORA or C1-C3 alkyl,wherein RA is C1-C4 alkyl optionally substituted with one or more halogen, cyano or nitro groups.The compounds are effective pro-drugs for urolithins and they enable the ready delivery of urolithins to the site in the digestive tract where they can be absorbed into the body.

An object of the present invention is to provide a method for eliminating the hydroxyl group at the 8-position of a urolithin to produce another kind of urolithin, and this object is achieved by a method for producing a second urolithin, comprising the Step (a): allowing, in a solution. containing a first urolithin, a microorganism having an ability to produce the second urolithin from the first urolithin to produce the second urolithin from the first urolithin.

An object of the present invention is to provide an effective and highly safe agent for inhibiting osteoclast differentiation, and a food or drink, pharmaceutical, supplement, and cosmetic that produce an osteoclast differentiation-inhibiting effect; and the object is fulfilled by an agent for inhibiting osteoclast differentiation, comprising a urolithin.

The subject invention is drawn to ellagitannin metabolites (e.g., urolithin) that find use in treating or preventing a neoplastic disease in a subject.

The invention discloses an environment-friendly long-acting metal antirust agent, and relates to the technical field of urolithin, in particular to an environment-friendly long-acting metal antirust agent. The environment-friendly long-acting metal antirust agent is prepared from the components in percentage by weight: 15-25% of sulfuric acid, 20-35% of citric acid, 3-10% of ethylene glycol, 1-3%of ethylenediamine tetraacetic acid, 0.1-0.5% of polyvinylpyrrolidone and the balance of water. According to the environment-friendly long-acting metal antirust agent, the sulfuric acid is an inorganic strong acid, has good dispersity, can be completely ionized in a solution, and is beneficial to improving the conductivity, the dispersing capacity and the anode current efficiency of a polishing solution, so that the surface of stainless steel is polished uniformly; and the citric acid is low in acidity and large in viscosity, can achieve a dissolving effect and form a passivation film on the surface of the stainless steel in the polishing process, and prevents over-corrosion of the stainless steel; and the ethylene glycol is adsorbed on the surface of an anode, is beneficial to promoting formation of a diffusion layer, can form a thin film on the surface of the stainless steel together with the citric acid, prevents over-corrosion of the stainless steel, and makes the surface of the polished stainless steel be bright and fine.